Press launch MHRA approves GLP –1 receptor agonist semaglutide to reduce possibility of great coronary heart challenges in obese or overweight Grownups Semaglutide is the initial weightloss drug permitted in the UK like a preventative therapy for anyone with established cardiovascular diseaseenhanced risk of low blood sugar (hypoglycemia), In par